Your browser doesn't support javascript.
loading
Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.
Hangiu, Oana; Compte, Marta; Dinesen, Anders; Navarro, Rocio; Tapia-Galisteo, Antonio; Mandrup, Ole A; Erce-Llamazares, Ainhoa; Lázaro-Gorines, Rodrigo; Nehme-Álvarez, Daniel; Domínguez-Alonso, Carmen; Harwood, Seandean L; Alfonso, Carlos; Blanco, Belen; Rubio-Pérez, Laura; Jiménez-Reinoso, Anaïs; Díez-Alonso, Laura; Blanco, Francisco J; Sanz, Laura; Howard, Kenneth A; Álvarez-Vallina, Luis.
Afiliação
  • Hangiu O; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario12 de Octubre, 28041 Madrid, Spain.
  • Compte M; Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.
  • Dinesen A; Department of Antibody Engineering, Leadartis SL, Madrid, Spain.
  • Navarro R; Department of Antibody Engineering, Leadartis SL, Madrid, Spain.
  • Tapia-Galisteo A; Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, Aarhus University, Aarhus C, Denmark.
  • Mandrup OA; Department of Antibody Engineering, Leadartis SL, Madrid, Spain.
  • Erce-Llamazares A; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario12 de Octubre, 28041 Madrid, Spain.
  • Lázaro-Gorines R; Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.
  • Nehme-Álvarez D; Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, Aarhus University, Aarhus C, Denmark.
  • Domínguez-Alonso C; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario12 de Octubre, 28041 Madrid, Spain.
  • Harwood SL; Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.
  • Alfonso C; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario12 de Octubre, 28041 Madrid, Spain.
  • Blanco B; Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.
  • Rubio-Pérez L; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario12 de Octubre, 28041 Madrid, Spain.
  • Jiménez-Reinoso A; Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.
  • Díez-Alonso L; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario12 de Octubre, 28041 Madrid, Spain.
  • Blanco FJ; Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.
  • Sanz L; Department of Molecular Biology and Genetics, Aarhus University, Aarhus C, Denmark.
  • Howard KA; Centro de Investigaciones Biológicas Margarita Salas (CIB), CSIC, Madrid 28040, Spain.
  • Álvarez-Vallina L; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario12 de Octubre, 28041 Madrid, Spain.
iScience ; 25(9): 104958, 2022 Sep 16.
Article em En | MEDLINE | ID: mdl-36072551
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article